Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 208

The DOI matches its Crossref record.

High serum interleukin‐6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B

Open access
Wong, Vincent Wai‐Sun, Yu, Jun, Cheng, Alfred Sze‐Lok, Wong, Grace Lai‐Hung, Chan, Hoi‐Yun, Chu, Eagle Siu‐Hong, Ng, Enders Kai‐On, Chan, Francis Ka‐Leung, Sung, Joseph Jao‐Yao, Chan, Henry Lik‐Yuen·2009·International Journal of Cancer

Abstract

Increased interleukin‐6 (IL‐6) production is implicated in the pathogenesis of hepatocellular carcinoma (HCC) in animal models. Although previous studies showed that HCC patients had higher serum IL‐6 level at the time of diagnosis, it is unclear if the cytokine contributes to the development of HCC or is just a reaction to cancer. To address this question, we performed a nested case‐control study. Consecutive chronic hepatitis B patients were recruited from 1997 to 2000 and followed till 2008. Profiling of 27 cytokines, chemokines and growth factors was performed at baseline, date of peak alanine aminotransferase (ALT) level and the last visit. Thirty‐seven patients developed HCC at a median follow‐up of 62 months (interquartile range: 41–110). Serum IL‐6 was higher in patients with HCC than controls both during peak ALT and at the last visit (both p = 0.02). Patients with IL‐6 above 7 pg/ml during peak ALT had increased risk of HCC or death (adjusted hazard ratio 3.0; 95% confidence interval 1.2, 7.8; p = 0.02). The sensitivity, specificity, positive and negative predictive values of this cutoff to predict future HCC development were 70%, 73%, 72% and 71%, respectively. Combination of IL‐6 and AFP improved the sensitivity in diagnosing HCC or predicting future HCC development. In conclusion, high serum IL‐6 level predates the development of HCC in chronic hepatitis B patients, and has moderate accuracy in predicting future cancer. This may assist clinicians in selecting high‐risk patients for HCC surveillance program. © 2009 UICC

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.24281

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 208

Metadata

Authors
Wong, V. W., Yu, J., Cheng, A. S., Wong, G. L., Chan, H., Chu, E. S., Ng, E. K., Chan, F. K., Sung, J. J., & Chan, H. L.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2009-03-06
Volume
124
Issue
12
Pages
2766-2770
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2022969414
Cited by
208
References
0
FWCI
9.22
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High serum interleukin‐6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. https://app.cochat.ai/papers/10.1002/ijc.24281
The paper
Wong, V. W., Yu, J., Cheng, A. S., Wong, G. L., Chan, H., Chu, E. S., Ng, E. K., Chan, F. K., Sung, J. J., & Chan, H. L. (2009). High serum interleukin‐6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. International Journal of Cancer. https://doi.org/10.1002/ijc.24281

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.